70 results about "CpG Oligodeoxynucleotide" patented technology

Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a CpG oligodeoxynucleotide. Also provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer, comprising administering an effective amount of the cancer therapeutic agent. The methods may also include reducing immunoregulatory T cell activity in the individual.

Disclosed is the therapeutic use of CpG oligodeoxynucleotides for skin diseases. The CpG oligodeoxynucleotides (CpG ODNs) of the present invention show excellent immunoactive effects against skin diseases in both cases of CpG ODNs with a phosphorothioate backbone and CpG ODNs with a phosphodiester backbone.

Mutations to the tumor suppressor protein p53 have been observed in 40-60% of all human cancers. These mutations are often associated with high nuclear and cytoplasmic concentrations of p53. Since many tumors exhibit highly elevated p53 levels, the protein is an attractive target for cancer immunotherapy. Unfortunately, p53 is an autoantigen that is likely to be tolerated as a self-protein by the immune system. The present invention is based on the discovery that this self-tolerance can be overcome by administration of recombinant modified vaccinia Ankara (MVA) containing a nucleic acid that encodes p53 (rMVAp53). The invention discloses a method of generating a p53-specific CTL-response to tumor cells expressing mutated p53 by administering a composition comprising rMVAp53. Administration of rMVAp53 decreases tumor development, tumor growth, and mortality in a variety of malignant cell types. These effects are enhanced by administration of CTLA-4 blocker and / or CpG oligodeoxynucleotide immunomodulators.

A composition that can be used as a vaccine containing means for targeting at least one antigen to dendritic cells and as adjuvants a granulocyte macrophage colony stimulating factor and a CpG oligodeoxynucleotide and / or a CpG-like oligodeoxynucleotide. This composition can used to treat cancers, infectious diseases caused by bacterial, viral, fungal, parasitic or protozoan infections, allergies and / or autoimmune diseases.

The invention discloses a mercaptyl-terminated (2-dimethylamino ethyl) polymethacrylic ester polymer, a self-assembled and modified nano-gold compound (PDMAEMAGNPs) of the polymer as well as a compound of the polymer and plasmid DNA; and the invention also discloses preparation methods of the polymer and the compounds as well as the application of all in carrier as genes. When the concentration ofthe compounds of PDMAEMAGNPs and GFP DNA (green fluorescent protein expression DNA) is 30Mug / mL, the transfection efficiency to HEK 293T cell is 30 percent, and the survival rate to HEK 293T cell, HeLa cell and 293 cell is more than 80 percent. The PDMAEMAGNPs / CpG ODN (human CpG oligodeoxynucleotide) compound has remarkable effects in gene therapy in vitro and in vivo. The suppression ratio to tumor growth of the PDMAEMAGNPs / p53 DNA (tumor suppressor gene) is 30-37 percent.

The present invention discloses a compound adjuvant for tuberculosis subunit vaccine, containing cationic liposome dimo-thylidioctyl ammonium bromide (DDA), TLR9 ligand CpG oligodeoxynucleotides 2395 and TLR3 ligand PolyICLC, and also provides the tuberculosis subunit vaccine and preparation method and application thereof. The beneficial effect of the invention is that the compound adjuvant for tuberculosis subunit vaccine provided by the present invention enhances the immunogenicity of the fusion protein of Mycobacterium tuberculosis, contributing to the induction of the tuberculosis fusion protein to Th1-type anti-tuberculosis immune response.

The invention discloses a preparation method and applications of hollow gold nanospheres modified by CpG oligodeoxynucleotide. Cobalt chloride is subjected to reduction by adopting sodium borohydride,thus cobalt nanoparticles are obtained, cobalt nanoparticles are adopted for carrying out reduction on chloroauric acid, and thus hollow gold nanospheres are prepared; CpG oligodeoxynucleotide, a surfactant and a buffer solution are added into a solution of the hollow gold nanospheres, shaking culture is carried out, and thus the hollow gold nanosphere material modified by CpG oligodeoxynucleotide is obtained. According to the technical scheme, by utilizing the property that the hollow gold nanospheres have the large loading capacity, CpG is loaded through the self-assembly effect, the synthesis method is simple, and the method is suitable for large-scale production and application; the cell uptake capacity of CpG oligodeoxynucleotide can be enhanced, and the biocompatibility is good; thehollow gold nanospheres modified by CpG oligodeoxynucleotide have the near-infrared surface plasma adsorbing effect, the primary tumor is eliminated by utilizing the photothermal ablation effect, a tumor antigen is generated in situ, under the promoting of CpG oligodeoxynucleotide, the antitumor immunity of the whole body is induced, and the distant metastasis tumor is further treated.

The invention discloses a method for quickly screening stichopus japonicus immune enhancers with high throughput, which is characterized by comprising the following steps: firstly determining beta-glucan, peptidoglycan, chitosan, mannan-oligosaccharide, CpG-oligodeoxynucleotide, soy peptide, lactoferrin, levamisole, vitamin C and vitamin E as the screened immune enhancers, then carrying out primary culture for stichopus japonicus coelom cells, detecting four sensitive immune indexes of the immune enhancers on stichopus japonicus by the cultured stichopus japonicus coelom cells, namely effects of phagotrophy rate, superoxide anion content, superoxide dismutase activity and nitric oxide synthase activity, and determining a screening result for the effects of the four indexes according to the immune enhancers. The method can screen the immune enhancers on large scale and in short time, and simultaneously can research the action mechanisms of the various immune enhancers and lay a foundation for the deep study of the immune enhancers.

The invention relates to a self-assembly nano adjuvant and a preparation method of a nano vaccine formed by the self-assembly nano adjuvant and application. The nano adjuvant comprises self-assembly materials of protamine sulfates and carboxymethyl glucan, the self-assembly materials and CpG oligodeoxynucleotides self-assembly form the nano adjuvant, and the nano vaccine is formed by the nano adjuvant and the virus antigen. The nano adjuvant increases the bioavailability of the CpG oligodeoxynucleotides, degradation in the body is avoided, and the B type CpG is added the function of A type CpG. The nano vaccine not only can induce the humoral immune response of TH1 type, but also induce relatively high cellular immune response. The unvaccinated experiments in mice body proves that the nanovaccine has good protection function, which provides help in the application of nano vaccine in the future.

The present invention relates to a modified CpG oligodeoxynucleotide (ODN) which is prepared by coupling a consecutive sequence of deoxyribothymine (dT) to the 3′-terminus of CpG ODN having immunoregularory function, thereby improving immunoactivity of splenocytes, macrophages and peripheral mononuclear cells, and therefore, can be effectively used as a vaccine adjuvant for preventing and treating hepatitis B or an anti-cancer agent. Since the phosphorothioate CpG ODN having the consecutive sequence of dT at its 3′-terminus shows high activity inducing Th-1 immune response and does not elicit in vivo toxicity with guaranteeing its safety, it can be effectively used as a vaccine adjuvant.

Pharmaceutical compositions are provided that include an antibiotics, but that include ingredients that counteract the effect of that antibiotic on wound healing, without altering the bactericidal properties of the antibiotic. These pharmaceutical compositions include an effective amount of 1) an imidazoquinoline having toll-like receptor 7 (TLR7) ligand activity, 2) an immunostimulatory K-type CpG oligodeoxynucleotide (ODN) comprising an unmethylated CpG motif, 3) an antibiotic, and 4) a surfactant, wherein the composition is formulated for topical administration. Methods for accelerating wound healing are also provided. These methods include topically administering the disclosed compositions. The wound can be in the skin or in the eye.

The invention provides an immunostimulatory composition, the immunostimulatory composition comprises saponin and CpG oligodeoxynucleotide, or the immunostimulatory composition is composed of an adjuvant containing the saponin, and the CpG oligodeoxynucleotide, wherein the CpG oligodeoxynucleotide sequence is provided with two or more copies of a 5'-TTCGTT-3' sequence motif or a 5'-TCGTCGTCG-3 'sequence motif. The invention provides the use of the immunostimulatory composition in the preparation of a medicament for the treatment of diseases.

The invention relates to an antigen and adjuvant co-delivery nanometer vaccine applied to liver cancer immunization therapy. Sodium alginate and polymine are used as carrier materials, liver cancer specific polypeptide antigen phosphatidylinositol proteoglycan 3127-136 peptides(GPC3127-136, AMFKNNYPSL) are used as immunizing antigens, CpG oligodeoxynucleotide is used as an adjuvant, and through static electricity interaction, the antigen and adjuvant co-delivery nanometer vaccine is prepared, wherein the mass ratio of the carrier materials to the immunizing antigens to the adjuvant is 1: (1-10): (0.3-0.8). The nanometer vaccine disclosed by the invention can increase the endocytosis quantity of dendritic cells (dendritic cell, DC) to the antigen and the adjuvant, and through raising costimulatory molecules on the surfaces of the DCs and promoting the secretion of cytokine of TNF-a, IL-6 and the like, arousing organisms to produce effective immune response is facilitated; and besides, the raw materials are cheap and easy to obtain, the preparation method is easy and easily repeated, large-scale processing and producing are easy, the liver cancer immunization therapy effects can be strengthened, and the antigen and adjuvant co-delivery nanometer vaccine has favorable application prospects.

The invention provides a fragment of CpG oligodeoxynucleotides sequence capable of stimulating proliferation activities of animal immunologic cells, and a method for packaging this fragment of CpG oligodeoxynucleotides to prepare anti-infection DNA nano granular formulation, the use of the CpG nano particles as novel anti-infection molecular immune enhancement agent is also disclosed. The method comprises packaging CpG oligodeoxynucleotides with chitosan nano particles, immunizing experimental animals with the prepared DNA nano granular formulation separately or synergically through intramuscular injection or oral administration, finally detecting the cell and body fluid immunity indexes of the experimental animal.

The invention relates to a self-assembly nanometer adjuvant and a preparing method and application of nanometer vaccine formed by the self-assembly nanometer adjuvant. According to the self-assembly nanometer adjuvant and the preparing method and application of the nanometer vaccine formed by the self-assembly nanometer adjuvant, protamine sulfate and carboxymethyl dextran serve as self-assembly materials, the protamine sulfate, the carboxymethyl dextran and CpG oligodeoxynucleotide form the nanometer adjuvant in a self-assembly manner, and the nanometer vaccine is formed by the nanometer adjuvant and a viral antigen. Through the nanometer adjuvant, the bioavailability of the CpG oligodeoxynucleotide is improved, it is avoided that the CpG oligodeoxynucleotide is degraded in the body, andfunctions of A-type CpG are increased through B-type CpG. Through the nanometer vaccine, a TH1-type humoral immunity response can be induced, and meanwhile a high cellular immune response can be induced. Mice in-vivo challenge experiments verify that the nanometer vaccine has a good protection effect, and provides help for future nanometer-vaccine application.

The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3′-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and β-1,3-glucan.

The invention provides a method for preparing an antigen composition capable of targeting glioma cells and glioma stem cells. The method comprises the steps of (1) providing isolated cell populations containing the glioma stem cells and the glioma cells; (2) amplifying the glioma stem cells in the cell populations; (3) carrying out freeze-thaw cracking treatment on the amplified cell populations so as to obtain the antigen composition containing glioma stem cell lysates and glioma cell lysates. The invention also provides a vaccine containing the antigen composition, dendritic cells and CpG oligodeoxynucleotide, and application of the vaccine in preparation of medicines for treating glioma. The antigen composition and the vaccine which are provided by the invention can target the glioma cells and the glioma stem cells at the same time, thus being capable of effectively killing the residue glioma stem cells and the glioma cells and further inhibiting the recurrence of the glioma.

Compositions including multiple oligodeoxynucleotides with a CpG motif are disclosed herein. The compositions can include either D or K type oligodeoxynucleotides. These compositions are of use in inducing an immune response in a large percentage of the individuals in a population.

The invention provides a CpG nucleic acid drug conveying system. The CpG nucleic acid drug conveying system is characterized in that the CpG nucleic acid drug conveying system comprises a vector and a CpG nucleic acid drug stored in the vector, 50-155[mu]g of the CpG nucleic acid drug is stored in 1mg of the vector, the vector is an amino silane coupling agent modied meso-porous silicon oxide nanoparticle, the particle size of the particle is 50-100nm, the meso-pore aperture is 2-15nm, and the CpG nucleic acid drug is CpG oligodeoxynucleotide, and contains 12-72 base pairs. The invention also provides a making method of the CpG nucleic acid drug conveying system. The CpG nucleic acid drug conveying system has a large CpG nucleic acid drug storage ability, and can be efficiently endocytosed into endosome by cells in order to substantially improve the secretion level of interleukin IL-6 and IgG antibody, so the pollen allergy inhibition and treatment effects are improved.

The present invention relates to a preferably nebulizable pharmaceutical composition comprising a pharmaceutically acceptable protein-based nanocarrier preferably in the size range 150 to 300 nm and a preventative or therapeutic amount of an active agent for use in the prevention and / or treatment of an allergic and / or inflammatory disease of the lower airways in a mammal. Preferably, the active agent is a CpG oligodeoxynucleotide (CpG-ODN), and preferably the composition exhibits a prolonged clinical effect.

CpG-oligodeoxynucleotides (CpG-ODN), as potent immune stimuli developed for using as adjuvant in different species, are disclosed herein. TLR9 is the cellular receptor for CpG-ODN, and current developed CpG-ODN has low activity to rabbit TLR9. Here, a type of CpG-ODN containing a GACGTT or AACGTT motif in about 11-14 deoxynucleotides was demonstrated to have potent immunostimulatory activity to rabbit TLR9, and capable of boosting a less toxic and potent antibody response in rabbits.

The present invention provides a pharmaceutical composition. The pharmaceutical composition comprises i) a herpes gE protein, an active fragment of the protein, a variant of the protein, or a mixture of at least two of the herpes gE protein, the active fragment of the protein and the variant of the protein; Ii) an immunostimulatory composition, wherein the immunostimulatory composition comprises a saponin and a CpG oligodeoxynucleotide, or the immunostimulatory composition comprises an adjuvant comprising the saponin, and the CpG oligodeoxynucleotide. The invention provides application of the pharmaceutical composition in preparation of a medicine for preventing and / or treating chicken pox-herpes zoster virus infection and / or chicken pox-herpes zoster virus mediated diseases. The pharmaceutical composition provided by the invention achieves an unexpected technical effect and can mediate stronger immune response.

Provided are methods and compositions for modulating an immune response or for treating a disease or condition in a subject, such as cancer, infection, autoimmune disease, allergy, and asthma. The methods involve systemically administering to a subject a particle comprising a surface and an interior, wherein the surface of the particle comprises an antigen, the interior of the particle comprises an immune modulating agent, and the subject is or has been primed to mount an antibody response to the antigen. The antibody response to the particle permits Fc receptor-bearing target cells to take up the particle, thereby delivering the immune modulating agent to the target cells and modulating an immune response of the subject. In various embodiments, the immune modulating agent can be selected from the group consisting of therapeutic agents, immune activators, and immune suppressors. In certain embodiments, the immune activator is a TLR agonist, e.g, a CpG oligodeoxynucleotide.